- Home
- EOI vs CATX Comparison
EOI vs CATX Comparison
Compare EOI & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOI
- CATX
- Stock Information
- Founded
- EOI 2004
- CATX 1983
- Country
- EOI United States
- CATX United States
- Employees
- EOI N/A
- CATX N/A
- Industry
- EOI Finance/Investors Services
- CATX Medical/Dental Instruments
- Sector
- EOI Finance
- CATX Health Care
- Exchange
- EOI Nasdaq
- CATX Nasdaq
- Market Cap
- EOI 827.9M
- CATX 782.7M
- IPO Year
- EOI N/A
- CATX N/A
- Fundamental
- Price
- EOI $20.78
- CATX $3.44
- Analyst Decision
- EOI
- CATX Strong Buy
- Analyst Count
- EOI 0
- CATX 9
- Target Price
- EOI N/A
- CATX $17.25
- AVG Volume (30 Days)
- EOI 83.6K
- CATX 1.2M
- Earning Date
- EOI 01-01-0001
- CATX 02-12-2025
- Dividend Yield
- EOI 7.19%
- CATX N/A
- EPS Growth
- EOI N/A
- CATX N/A
- EPS
- EOI N/A
- CATX N/A
- Revenue
- EOI N/A
- CATX $1,557,000.00
- Revenue This Year
- EOI N/A
- CATX N/A
- Revenue Next Year
- EOI N/A
- CATX N/A
- P/E Ratio
- EOI N/A
- CATX N/A
- Revenue Growth
- EOI N/A
- CATX N/A
- 52 Week Low
- EOI $14.36
- CATX $2.70
- 52 Week High
- EOI $18.88
- CATX $19.10
- Technical
- Relative Strength Index (RSI)
- EOI 47.60
- CATX 41.92
- Support Level
- EOI $19.98
- CATX $3.02
- Resistance Level
- EOI $20.74
- CATX $3.74
- Average True Range (ATR)
- EOI 0.33
- CATX 0.26
- MACD
- EOI -0.02
- CATX 0.16
- Stochastic Oscillator
- EOI 60.69
- CATX 60.90
About EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.